Bill

Bill > LB1222


NE LB1222

NE LB1222
Require insurance coverage of acquired brain injury services and require insurance and medicaid coverage of certain testing and treatments for Alzheimer's disease and related dementia


summary

Introduced
01/21/2026
In Committee
01/23/2026
Crossed Over
Passed
Dead

Introduced Session

Potential new amendment
109th Legislature

Bill Summary

A BILL FOR AN ACT relating to public health and welfare; to require insurance coverage of acquired brain injury services as prescribed; to define terms; to require an expedited appeal process; to provide duties for the Department of Insurance; and to require insurance and medicaid coverage for diagnostic testing and treatments or medications prescribed to slow the progression of Alzheimer's disease and related dementia.

AI Summary

This bill mandates that by January 1, 2027, insurance policies and self-funded employee benefit plans (to the extent not restricted by federal law) must cover medically necessary treatments for acquired brain injuries, which are defined as brain injuries occurring after birth due to various causes like infections, strokes, or traumatic events. This coverage cannot have lifetime or annual limits that contradict accepted medical standards and must treat inpatient rehabilitation limitations separately from post-acute rehabilitation services like outpatient day treatment or community reintegration. Furthermore, the bill requires an expedited appeal process for denials of acquired brain injury services, with decisions made within five business days, and ongoing rehabilitation coverage must continue during an appeal if interrupting it risks regression. The Department of Insurance will oversee compliance and report annually on coverage decisions and denials. Additionally, by January 1, 2028, insurance policies, self-funded plans, and the state's Medicaid program (medical assistance program) must cover medically necessary diagnostic testing and treatments or medications approved by the Food and Drug Administration (FDA) that are prescribed to slow the progression of Alzheimer's disease and related dementias, and this coverage cannot be subject to "step-therapy," a requirement that patients try less expensive treatments first.

Committee Categories

Business and Industry

Sponsors (1)

Last Action

Banking, Commerce and Insurance Hearing (13:30:00 2/24/2026 Room 1507) (on 02/24/2026)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...